DPP-4 inhibitors and their potential role in the management of type 2 diabetes - BARNETT, A. (International journal of clinical practice (Esher), 2006)
Keywords: Adamantane - adverse effects; Adamantane - analogs & derivatives; Adamantane - therapeutic use; Adenosine Deaminase Inhibitors; Animals; Biological and medical sciences; Blood Glucose - drug effects; Diabetes Mellitus, Type 2 - drug therapy; Diabetes. Impaired glucose tolerance; Dipeptides - adverse effects; Dipeptides - therapeutic use; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; DPP-4 inhibitor; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; General aspects; Glycoproteins - antagonists & inhibitors; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Medical sciences; Models, Animal; Nitriles; Pyrazines - adverse effects; Pyrazines - therapeutic use; Pyrrolidines; saxagliptin; sitagliptin; Sitagliptin Phosphate; Triazoles - adverse effects; Triazoles - therapeutic use; type 2 diabetes; vildagliptin; Endocrinopathy; Type 2 diabetes; Medicine; Clinical management; Treatment; sitagliptin; DPP-4 inhibitor; vildagliptin; Metabolic diseases; saxagliptin; Inhibitor; Vildagliptin